CD8A and cervical squamous cell carcinoma: In a related Phase II neoadjuvant study, the COLIBRI trial combined nivolumab and ipilimumab in locally advanced cervical squamous cell carcinoma (FIGO stages IB3–IVA), resulting in impressive outcomes such as significant CD8+ T-cell infiltration, high complete response rates (82.5%), and low progression rates (10%), particularly in stage III-C disease (114).